Resources
32 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/17/2021 (updated 4/10/2024)
New medications for office-based treatment of opioid
addiction are comparable in efficacy to other chronic
conditions such as diabetes, asthma, and hypertension
when combined with other interventions and as part of a
comprehensive care plan. They are safe, highly effective,
can be prescribed and/or administered at the Community
Health Center, with a sustainable business plan.
Posted 5/10/2021 (updated 4/10/2024)
Participants will be provided an overview on how to appropriately document, code and bill for encounters throughout the SUD/OUD continuum of care following CMS billing rules for FQHCs/RHC. An overview of the opportunities and challenges associated with MAT reimbursement mechanisms including coding and billing for Medicare, managed care, Medicaid, and other third-party payors will also be presented as will a brief description of revenue options for reporting Transitional Care Management, Virtual Communication Services, Telehealth, and other care management services such as Behavioral Health Integration and the Psychiatric Collaborative Care Model.
Posted 3/25/2021 (updated 4/5/2024)
Considerations for Addressing Neonatal Abstinence Syndrome (NAS)
Dr. Lopata, JBS NAS Technical Expert Leads, and NAS RCORP grantees from the Western Regions will discuss resources, stigma, best practices, and challenges in addressing NAS.
Posted 3/6/2021 (updated 4/5/2024)
HepVu released new interactive maps visualizing U.S. county-level Hepatitis C-related mortality, illustrating how factors such as age and geographic region affect health outcomes. Published in Hepatology, the data demonstrate that Hepatitis C-related mortality has been decreasing across the U.S. since 2013
Posted 2/17/2021 (updated 4/4/2024)
This packet presents you with the tools, materials and resources necessary to kick off grant activities quickly and efficiently.
Posted 12/23/2020 (updated 4/4/2024)
This article presents an important look into stigma of families impacted by NAS and the ways in which healthcare providers must work to combat stigma’s harmful effects, and explores directions for future research of strategies for reducing stigma amongst this population to improve engagement in healthcare and positive heath-seeking behaviors. The authors reported that mothers of infants with NAS experience intensified stigma surrounding SUDs and the challenge of overcoming exclusion, shame, and judgement of their ability to parent. In examining nurses’ perceptions of perinatal women with SUD, the authors found that many struggled with negative attitudes and prejudices towards mothers of infants with NAS that interfered with their ability to provide nonjudgmental care. The authors urge nurses to implement substantial strategies for addressing stigma through tools such as the ACTS script.
Posted 12/16/2020 (updated 4/4/2024)
As states seek new tools to meet the needs of individuals with substance use disorder (SUD) and opioid use disorder, federally qualified health centers (FQHCs) offer unique resources and examples for developing integrated and cost-effective health care services for complex and chronic conditions. The National Academy for State Health Policy developed this toolkit to share innovations, resources, and lessons learned from five state teams (AL, IL, SD, VA, and WI) that are working to strengthen the capacity of their FQHCs to deliver SUD care
Posted 10/26/2021 (updated 4/3/2024)
Posted 12/9/2020 (updated 4/3/2024)
Detailed risk benefit assessment of medications, settings and patient outcomes. These guidelines were developed in response to a resolution from the United Nations Economic and Social Council (ECOSOC), “to develop and publish minimum requirements and international guidelines on psychosocially assisted pharmacological treatment of persons dependent on opioids”
Posted 11/10/2020 (updated 4/3/2024)
In the context of the trends in Oregon SUD metrics and the increasing infectious complications related to IDU in other jurisdictions and their implications for HIV and HCV transmission, we sought to 1) describe statewide trends in IDU-related serious bacterial infections (SBI) hospitalizations overall and by SBI type and drug use diagnosis, 2) assess IDU-related SBI diagnoses among individuals living with HIV and HCV, and 3) and determine the annual costs of IDU-related SBI overall and by SBI type.